{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:07:43Z","timestamp":1792976863425,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41416-019-0452-3","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T23:03:48Z","timestamp":1555455828000},"page":"975-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours"],"prefix":"10.1038","volume":"120","author":[{"given":"Gabriel","family":"Mak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Blagden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Nebot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolly","family":"Mazumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Rogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Rizzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Tolson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt R.","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik-Tobias","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,17]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1647","volume":"5","author":"GW McLean","year":"2005","unstructured":"McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G. & Frame, M. C. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat. Rev. Cancer 5, 505\u2013515 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"452_CR2","first-page":"2417","volume":"6","author":"WG Cance","year":"2000","unstructured":"Cance, W. G., Harris, J. E., Iacocca, M. V., Roche, E., Yang, X., Chang, J. et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin. Cancer Res. 6, 2417\u20132423 (2000).","journal-title":"Clin. Cancer Res."},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2353\/ajpath.2010.100172","volume":"177","author":"IR Lai","year":"2010","unstructured":"Lai, I. R., Chu, P. Y., Lin, H. S., Liou, J. Y., Jan, Y. J., Lee, J. C. et al. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am. J. Pathol. 177, 1629\u20131637 (2010).","journal-title":"Am. J. Pathol."},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-03-3005","volume":"64","author":"C Recher","year":"2004","unstructured":"Recher, C., Ysebaert, L., Beyne-Rauzy, O., Mansat-De Mas, V., Ruidavets, J. B., Cariven, P. et al. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 64, 3191\u20133197 (2004).","journal-title":"Cancer Res."},{"key":"452_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0002-9440(10)63370-6","volume":"165","author":"AK Sood","year":"2004","unstructured":"Sood, A. K., Coffin, J. E., Schneider, G. B., Fletcher, M. S., DeYoung, B. R., Gruman, L. M. et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am. J. Pathol. 165, 1087\u20131095 (2004).","journal-title":"Am. J. Pathol."},{"key":"452_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0959-8049(12)72185-8","volume":"48","author":"KR Auger","year":"2012","unstructured":"Auger, K. R., Smitheman, K. N., Korenchuk, S., McHugh, C., Kruger, R., Van Aller, G. S. et al. Focal adhesion kinase inhibitor GSK2256098: a potent and selective inhibitor for the treatment of cancer. Eur. J. Cancer 48, 118 (2012).","journal-title":"Eur. J. Cancer"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria, J. C., Gan, H. K., Blagden, S. P., Plummer, R., Arkenau, H. T., Ranson, M. et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann. Oncol. 27, 2268\u20132274 (2016).","journal-title":"Ann. Oncol."},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444\u2013451 (2015).","journal-title":"Lancet"},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","volume":"332","author":"JA Tamminen","year":"2015","unstructured":"Tamminen, J. A., Yin, M., Ronty, M., Sutinen, E., Pasternack, A., Ritvos, O. et al. Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth. Exp. Cell Res. 332, 102\u2013115 (2015).","journal-title":"Exp. Cell Res."},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1369\/jhc.5A6807.2006","volume":"54","author":"M Melo de","year":"2006","unstructured":"de Melo, M., Gerbase, M. W., Curran, J. & Pache, J. C. Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J. Histochem. Cytochem. 54, 855\u2013861 (2006).","journal-title":"J. Histochem. Cytochem."},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/cncr.21014","volume":"103","author":"L Vintman","year":"2005","unstructured":"Vintman, L., Nielsen, S., Berner, A., Reich, R. & Davidson, B. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 103, 2427\u20132433 (2005).","journal-title":"Cancer"},{"key":"452_CR12","unstructured":"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) Tablets, for Oral Use. Prescribing Information \n                    https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/mekinist.pdf\n                    \n                   (2017)."},{"key":"452_CR13","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\n                    \n                   (2009)."},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257\u2013260 (2004).","journal-title":"Ann. Oncol."},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","volume":"13","author":"JR Infante","year":"2012","unstructured":"Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C. et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet. Oncol. 13, 773\u2013781 (2012).","journal-title":"Lancet. Oncol."},{"issue":"15 Supplement","key":"452_CR17","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/1538-7445.AM2015-2581","volume":"75","author":"Hiroyuki Cho","year":"2015","unstructured":"Cho, H., Matsumoto, S., Fujita, Y., Kuroda, A., Hashimoto, M., Takuwa, T. et al. Antitumor effect of Trametinib, a selective MEK inhibitor, in combination with 4- methylumbelliferone, a hyaluronic acid synthesis inhibitor, in Malignant pleural mesothelioma cell lines. Cancer Res. 75:2581 (2015).","journal-title":"Cancer Research"},{"key":"452_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.molonc.2016.06.005","volume":"10","author":"M Meerang","year":"2016","unstructured":"Meerang, M., Berard, K., Friess, M., Bitanihirwe, B. K., Soltermann, A., Vrugt, B. et al. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Mol. Oncol. 10, 1255\u20131265 (2016).","journal-title":"Mol. Oncol."},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos, P. I., Xiao, G. H., Gallagher, R., Jablonski, S., Jhanwar, S. C. & Testa, J. R. Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25, 5960\u20135968 (2006).","journal-title":"Oncogene"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0452-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0452-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0452-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:45Z","timestamp":1684616685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0452-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,17]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0452-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,17]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"At the time of the clinical study, R.A.F, N.N, J.M., D.R., L.Y., J.T., and K.R.A. were employees of GlaxoSmithKline. R.P. and J-C.S. have received honoraria or consultancy fees from GSK. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice, the Declaration of Helsinki 2008 and applicable country-specific requirements. Prior to the study, ethics committee and institutional review board approval were obtained from MHRA Health Research Authority NRES Committee North West-Haydock (Manchester, UK) and CPP \u00cele-de-France III, H\u00f4pital Tarnier (Paris, France). All subjects provided written informed consent before any study specific procedures were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Summaries of the study protocol and results are available from . Anonymized individual participant data and study documents can be requested for further research from .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}